GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evoke Pharma Inc (STU:EV00) » Definitions » Cyclically Adjusted PB Ratio

Evoke Pharma (STU:EV00) Cyclically Adjusted PB Ratio : 0.09 (As of May. 17, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Evoke Pharma Cyclically Adjusted PB Ratio?

As of today (2024-05-17), Evoke Pharma's current share price is €0.50. Evoke Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was €5.71. Evoke Pharma's Cyclically Adjusted PB Ratio for today is 0.09.

The historical rank and industry rank for Evoke Pharma's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:EV00' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.07   Med: 0.33   Max: 4.82
Current: 0.07

During the past years, Evoke Pharma's highest Cyclically Adjusted PB Ratio was 4.82. The lowest was 0.07. And the median was 0.33.

STU:EV00's Cyclically Adjusted PB Ratio is ranked better than
95.53% of 671 companies
in the Drug Manufacturers industry
Industry Median: 1.88 vs STU:EV00: 0.07

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Evoke Pharma's adjusted book value per share data for the three months ended in Dec. 2023 was €-0.708. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €5.71 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Evoke Pharma Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Evoke Pharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evoke Pharma Cyclically Adjusted PB Ratio Chart

Evoke Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 4.05 0.32 0.17

Evoke Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.22 0.18 0.18 0.17

Competitive Comparison of Evoke Pharma's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Evoke Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evoke Pharma's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evoke Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Evoke Pharma's Cyclically Adjusted PB Ratio falls into.



Evoke Pharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Evoke Pharma's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.50/5.71
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evoke Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Evoke Pharma's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.708/129.4194*129.4194
=-0.708

Current CPI (Dec. 2023) = 129.4194.

Evoke Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201403 26.245 99.695 34.070
201406 21.964 100.560 28.268
201409 17.811 100.428 22.953
201412 14.631 99.070 19.113
201503 11.506 99.621 14.948
201506 7.311 100.684 9.398
201509 8.009 100.392 10.325
201512 5.300 99.792 6.873
201603 1.128 100.470 1.453
201606 -2.236 101.688 -2.846
201609 4.071 101.861 5.172
201612 3.489 101.863 4.433
201703 5.785 102.862 7.279
201706 4.698 103.349 5.883
201709 1.345 104.136 1.672
201712 1.425 104.011 1.773
201803 2.723 105.290 3.347
201806 3.258 106.317 3.966
201809 3.192 106.507 3.879
201812 2.436 105.998 2.974
201903 1.826 107.251 2.203
201906 2.795 108.070 3.347
201909 2.326 108.329 2.779
201912 1.937 108.420 2.312
202003 1.297 108.902 1.541
202006 -0.153 108.767 -0.182
202009 -0.744 109.815 -0.877
202012 -1.191 109.897 -1.403
202103 2.432 111.754 2.816
202106 1.832 114.631 2.068
202109 1.491 115.734 1.667
202112 1.156 117.630 1.272
202203 0.640 121.301 0.683
202206 2.035 125.017 2.107
202209 1.672 125.227 1.728
202212 1.153 125.222 1.192
202303 0.594 127.348 0.604
202306 0.149 128.729 0.150
202309 -0.245 129.860 -0.244
202312 -0.708 129.419 -0.708

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Evoke Pharma  (STU:EV00) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Evoke Pharma Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Evoke Pharma's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Evoke Pharma (STU:EV00) Business Description

Traded in Other Exchanges
Address
420 Stevens Avenue, Suite 370, Solana Beach, CA, USA, 92075
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.

Evoke Pharma (STU:EV00) Headlines

No Headlines